AR065300A1 - Compuestos quimicos derivados de 1,2-pirazol - Google Patents

Compuestos quimicos derivados de 1,2-pirazol

Info

Publication number
AR065300A1
AR065300A1 ARP080100584A ARP080100584A AR065300A1 AR 065300 A1 AR065300 A1 AR 065300A1 AR P080100584 A ARP080100584 A AR P080100584A AR P080100584 A ARP080100584 A AR P080100584A AR 065300 A1 AR065300 A1 AR 065300A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
independently selected
cyano
halo
Prior art date
Application number
ARP080100584A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39438215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR065300A1 publication Critical patent/AR065300A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos utiles en la inhibicion de 11betaHSD1; procesos para su elaboracion y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de la formula (1): donde: Q es O, S o un enlace simple; R1 es alquilo C1-6, alquenilo C2- 6, alquinilo C2-6, cicloalquilo C3-7, heterociclilo, aril-alquiIoC1-3, heteroariI-alquiloC1-3, cicloalquilC3-7-alquiloC1-3, cicloalquilC3-7-alqueniloC2-3 o cicloalquilC3-7-alquiniloC2-3 [donde cada sin esta opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de manera independiente de alquilo C1-3, hidroxi, halo, oxo, ciano, trifluormetilo, alcoxi C1-3, alquiloC1-3S(O)n- (donde n es 0, 1, 2 o 3), R5CON(R5')-, (R5)(R5'')NC(O)-, R5'C(O)O-, R5'OC(O)-, (R5')(R5'')NC(O)N(R5ö')-, R5SO2N(R5'')- y (R5')(R5ö)NSO2- (donde R5 es alquilo C1-3 opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de hidroxilo, halo o ciano; y R5' y R5''se seleccionan de manera independiente de hidrogeno y alquilo C1-3 opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de manera independiente de hidroxilo, halo, alcoxi C1-3, carboxi y ciano; o R5' y R5'' junto con el átomo de nitrogeno al cual están unidos forman un anillo saturado de 4 a 7 miembros )]; R2 se selecciona de heterociclilo, cicloalquiloC3-7(CH2)m-, y policicloalquiloC6-12(CH2)m- (donde m es 0, 1 o 2, y los anillos están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados de manera independiente de R6); R3 se selecciona de hidrogeno, aIquilo C1-4, cicloalquilo C3-5 y cicloalquilmetilo C3-5 (donde cada uno está opcionalmente sustituido con 1, 2 o 3 átomos de fluor); R2 y R3 junto con el átomo de nitrogeno al cual están unidos forman un sistema de anillo monocíclico, bicíclico o puenteado, saturado, que, en forma opcional, contiene 1 o 2 heteroátomos de anillo adicionales seleccionados de nitrogeno, oxígeno y azufre, y que está opcionalmente fusionado a un anillo monocíclico saturado, parcialmente saturado o insaturado, donde el sistema de anillo resultante está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de modo independiente de R7; R6 y R7 se seleccionan de manera independiente de hidroxilo, halo, oxo, carboxi, ciano, trifluormetilo, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9'')NC(O)-, (R9')(R9ö)N-, R9S(O)a- donde a es 0 a 2, R9'OC(O)-, (R9')(R9ö)NSO2-, R9SO2N(R9)-, (R9')(R9ö)NC(O)N(R9'')-, fenilo y heteroarilo [donde los grupos fenilo y heteroarilo están opcionalmente fusionados a un fenilo, heteroarilo o un anillo de 5 o 6 miembros saturado o parcialmente saturado que, en forma opcional, contiene 1, 2 o 3 heteroátomos seleccionados de manera independiente de nitrogeno, oxígeno y azufre, donde el sistema de anillo resultante está opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de modo independiente de alquilo C1-4, hidroxilo, ciano, trifluormetilo, trifluormetoxi, halo, alcoxi C1-4, alcoxiC1-4-alquiloC1-4, amino, N- alquilaminoC1-4, di-N,N-(alquilo C1-4)amino, N-alquilcarbamoiloC1-4, di-N,N-(alquilo C1-4)carbamoilo, alquilC1-4S(O)r-, alquilC1-4S(O)alquiIoC1-4 (donde r es 0, 1 u 2)]; R9 se selecciona de manera independiente de alquilo C1-3 opcionalmenle sustituido con hidroxilo, hato, alcoxi C1-4, carboxi o ciano; R9', R9ö y R9''' se seleccionan de manera independiente de hidrogeno y alquilo C1-3 opcionalmente sustituido con 1, 2, o 3 sustituyentes seleccionados de manera independiente de hidroxilo, halo, alcoxi C1-4, carboxi y ciano; A es un anillo fenilo o heteroarilo (donde el anillo fenilo o heteroarilo está opcionalmente sustituido en átomos de carbono del anillo, con 1, 2 u 3 grupos R10, y en un nitrogeno de anillo disponible en un grupo heteroarilo, con R11); R10 se selecciona de manera independiente de alquilo C1-4, hidroxilo, ciano, trifluormetilo, trifluormetoxi, halo, alcoxi C1-4, alcoxiC1-4-alquiloC1-4, amino, N-alquilaminoC1-4, di-N,N-(alquilo C1-4)amino, N- alquilcarbamoíloC1-4, di-N,N-(alquilo C1-4)carbamoílo, aIquiloC1-4S(O)s-, alquiloC1-4S(O)salquiloC1-4 (donde s es 0, 1 o 2)]; R11 es, de manera independiente, alquilo C1-3 opcionalmente sustituido con 1, 2 o 3 átomos de fluor; X es un enlace directo, cicloalcanodiílo C3-4, cicloalcanilideno C3-4, -C(R12)(R13)-, -C(R12)(R13)C(R14)(R15)-, -CH2O- o -CH2S(O)t- (donde t es 0, 1 o 2): Y es un enlace directo, cicloalcanodiílo C3-4, cicloalcanilideno C3-4, -C(R16)(R17)- o - C(R18)(R19)C(R20)(R21)-; donde R12, R13, R14, R15, R16, R17, R18, R19, R20 y R21se seleccionan de manera independiente de hidrogeno y metilo; o una de sus sales aceptables para uso farmacéutico.
ARP080100584A 2007-02-12 2008-02-11 Compuestos quimicos derivados de 1,2-pirazol AR065300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88933607P 2007-02-12 2007-02-12
US98573507P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
AR065300A1 true AR065300A1 (es) 2009-05-27

Family

ID=39438215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100584A AR065300A1 (es) 2007-02-12 2008-02-11 Compuestos quimicos derivados de 1,2-pirazol

Country Status (23)

Country Link
US (2) US7816391B2 (es)
EP (2) EP2124937A1 (es)
JP (1) JP2010518063A (es)
KR (1) KR20090108726A (es)
CN (1) CN102503891A (es)
AR (1) AR065300A1 (es)
AU (1) AU2008215976B2 (es)
BR (1) BRPI0808450A2 (es)
CA (1) CA2676154A1 (es)
CL (1) CL2008000422A1 (es)
CO (1) CO6220949A2 (es)
EC (1) ECSP099571A (es)
IL (1) IL200047A0 (es)
MX (1) MX2009008506A (es)
NZ (1) NZ578568A (es)
PE (2) PE20090649A1 (es)
RU (2) RU2462456C2 (es)
SA (1) SA08290055B1 (es)
SG (1) SG177892A1 (es)
TW (1) TW200836719A (es)
UY (1) UY30912A1 (es)
WO (1) WO2008099145A1 (es)
ZA (1) ZA201000838B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659659B (zh) 2005-11-21 2014-07-23 盐野义制药株式会社 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CA2689659C (en) 2007-05-18 2012-10-23 Shionogi And Co., Ltd. Nitrogen-containing heterocyclic derivative having 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitory activity
EP2178845B1 (en) 2007-07-17 2013-06-19 F. Hoffmann-La Roche AG Inhibitors of 11b-hydroxysteroid dehydrogenase
AU2009211215B2 (en) * 2008-02-04 2011-11-03 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
AU2009239794A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
CN102300851A (zh) * 2009-01-30 2011-12-28 阿斯利康(瑞典)有限公司 制备含羧基的吡唑酰氨基化合物597的新方法
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
GB201004301D0 (en) * 2010-03-15 2010-04-28 Syngenta Participations Ag Process
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
US9012657B2 (en) 2011-06-22 2015-04-21 Central Glass Company, Limited Method for producing pyrazole compound
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015129094A (ja) * 2012-04-16 2015-07-16 大日本住友製薬株式会社 アリールアミノピラゾール誘導体
WO2019042267A1 (zh) * 2017-08-28 2019-03-07 中国医学科学院药物研究所 吡咯-2-甲酰胺类化合物及其制备方法和用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) 1978-02-21 1981-03-27 Delalande Sa
US4816391A (en) * 1984-02-29 1989-03-28 Syntex (U.S.A.) Inc. Amine stabilized aminoglycoside formulations
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
MY123528A (en) 1999-09-16 2006-05-31 Mitsubihsi Tanabe Pharma Corp Aromatic nitrogen-containing 6-membered cyclic compounds.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
IL155202A0 (en) 2000-10-20 2003-11-23 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005528395A (ja) 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7432287B2 (en) 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11-β-羟甾类脱氢酶-1抑制剂的吡唑甲酰胺类
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
KR20060101772A (ko) 2003-12-19 2006-09-26 화이자 인코포레이티드 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-hsd-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물
BRPI0510623A (pt) 2004-05-06 2007-10-30 Pfizer compostos de derivados de prolina e morfolina
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
PT1763517E (pt) 2004-06-28 2011-07-01 Hoffmann La Roche Derivados de pirimidina como inibidores 11beta-hsd1
WO2006048750A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006050476A2 (en) 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
KR101496206B1 (ko) 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
ES2369389T3 (es) 2005-04-05 2011-11-30 F. Hoffmann-La Roche Ag 1h-pirazol-4-carboxamidas, su preparación y su empleo como inhibidores de 11-beta- hidroxiesteroide dehidrogenasa.
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US20110059941A1 (en) 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
EP1894919B1 (en) 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
KR100970294B1 (ko) * 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
AU2006257646A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-YL)-sulfonamide derivatives
BRPI0622262A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
US8680122B2 (en) 2005-11-01 2014-03-25 Janssen Pharmacetica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
CN102659659B (zh) * 2005-11-21 2014-07-23 盐野义制药株式会社 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物
WO2007089683A1 (en) 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007107470A2 (en) * 2006-03-22 2007-09-27 F. Hoffmann-La Roche Ag Pyrazoles as 11-beta-hsd-1
CA2648074A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
WO2007125049A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CA2689659C (en) 2007-05-18 2012-10-23 Shionogi And Co., Ltd. Nitrogen-containing heterocyclic derivative having 11.beta.-hydroxysteroid dehydrogenase type 1 inhibitory activity
EP2178845B1 (en) 2007-07-17 2013-06-19 F. Hoffmann-La Roche AG Inhibitors of 11b-hydroxysteroid dehydrogenase
MX2010005048A (es) 2007-11-06 2010-07-28 Astrazeneca Ab Acido 4-[4-(2-adamantilcarbamoil)-5-terc-butil-pirazol-1-il]benzoi c-465.
AU2009211215B2 (en) 2008-02-04 2011-11-03 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
AU2009239794A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
CN102300851A (zh) 2009-01-30 2011-12-28 阿斯利康(瑞典)有限公司 制备含羧基的吡唑酰氨基化合物597的新方法
TW201118085A (en) 2009-10-20 2011-06-01 Astrazeneca Ab Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-β-HSD1

Also Published As

Publication number Publication date
IL200047A0 (en) 2010-04-15
CN102503891A (zh) 2012-06-20
CO6220949A2 (es) 2010-11-19
WO2008099145A1 (en) 2008-08-21
RU2012125372A (ru) 2013-12-27
EP2292228A1 (en) 2011-03-09
TW200836719A (en) 2008-09-16
BRPI0808450A2 (pt) 2014-08-12
SG177892A1 (en) 2012-02-28
US7816391B2 (en) 2010-10-19
RU2462456C2 (ru) 2012-09-27
US20090221663A1 (en) 2009-09-03
ZA201000838B (en) 2010-10-27
PE20120355A1 (es) 2012-05-17
ECSP099571A (es) 2009-09-29
KR20090108726A (ko) 2009-10-16
AU2008215976B2 (en) 2011-11-24
RU2009133259A (ru) 2011-03-20
JP2010518063A (ja) 2010-05-27
US8344016B2 (en) 2013-01-01
PE20090649A1 (es) 2009-06-26
MX2009008506A (es) 2009-10-12
SA08290055B1 (ar) 2012-09-26
US20110224273A1 (en) 2011-09-15
UY30912A1 (es) 2008-09-30
EP2124937A1 (en) 2009-12-02
AU2008215976A1 (en) 2008-08-21
NZ578568A (en) 2012-01-12
CA2676154A1 (en) 2008-08-21
CL2008000422A1 (es) 2009-01-02

Similar Documents

Publication Publication Date Title
AR065300A1 (es) Compuestos quimicos derivados de 1,2-pirazol
AR071387A1 (es) Pirimidin-5-carboxamidas sustituidas
AR038888A1 (es) Amidas heterociclicas
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
PE20011166A1 (es) Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
AR045955A1 (es) Compuestos benzoimidazolicos
AR070801A1 (es) Derivados pirimidin -piridina
AR044011A1 (es) Antagonistas de mchr1 heterociclicos
TW200732309A (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
MXPA05009059A (es) Derivados de heteroarilcarbamoilbenceno.
PE20120993A1 (es) Derivados bifenilicos como antivirales
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR082391A1 (es) Inhibidores biciclicos de acetil-coa y usos de los mismos
DE602006018152D1 (de) Triazolderivate als modulatoren von dopamin-d3-rezeptoren
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
TW200745061A (en) Macrocylic inhibitors of hepatitis C virus
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal